Compare HIT & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HIT | THAR |
|---|---|---|
| Founded | 1964 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.4M | 82.7M |
| IPO Year | 2024 | 2022 |
| Metric | HIT | THAR |
|---|---|---|
| Price | $1.38 | $2.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 624.5K | 340.9K |
| Earning Date | 11-10-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $30,723,490.00 | N/A |
| Revenue This Year | $70.02 | N/A |
| Revenue Next Year | $44.08 | N/A |
| P/E Ratio | $64.30 | ★ N/A |
| Revenue Growth | ★ 55.15 | N/A |
| 52 Week Low | $0.51 | $0.95 |
| 52 Week High | $7.59 | $9.08 |
| Indicator | HIT | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 44.38 | 42.90 |
| Support Level | $1.03 | $2.20 |
| Resistance Level | $1.46 | $2.57 |
| Average True Range (ATR) | 0.17 | 0.17 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 61.40 | 30.91 |
Health In Tech Inc is an insurance technology platform company. It offers a marketplace that processes in the healthcare industry through vertical integration, process simplification, and automation. The group removed friction and complexities, it streamlined the underwriting, sales, and service process for insurance companies, licensed brokers, and TPAs.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.